The purpose of this study is to:
* evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
Has a body mass index (BMI) of ≥27 kg/m² and <40 kg/m²
Is an adult patient with a confirmed diagnosis of T2DM
Has a hemoglobin A1c (HbA1c) ≥7% to <10.5%
Has a BMI of ≥25 kg/m² and <45 kg/m²
Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
Receiving therapies for chronic weight management or antidiabetic medications other than metformin and SGLT2i
Alnylam Pharmaceuticals
Lead sponsor